Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 19, 2025 · Filed Sep 23, 2025
The CEO of Biocardia paid $60K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month. Shares held went up 28% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$60,000
Shares × reported transaction price
$25K–$100K
+28.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 26 earlier confirmed purchases
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 12% of the CEO's reported total pay for fiscal 2024 ($493K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2025-11-03. The proxy names Peter Altman as CEO for that year. A size comparison, not a judgement
39 days after results of Aug 11, 2025, 54 days before results of Nov 12, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
3 BCDA insiders bought within the same week. That happened 7 times before in filings since 2007, most recently Jun 2025. Traded 5 days before BCDA filed an 8-K: received a notice from its stock exchange (Sep 24, 2025). Peter Altman's largest purchase of BCDA in their filings since 2018
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −10.1% | +1.1% | −11.3% |
| 30 days | −6.1% | +2.4% | −8.5% |
| 90 days | −14.2% | +4.1% | −18.3% |
| 180 days | −18.9% | −0.9% | −18.1% |
| 365 days | −27.7% | +16.1% | −43.8% |
Past results only. Not a forecast.
Insider buying
3 insiders in a week, 8th time since 2007Traded Sep 19, 2025 · filed 4 days later
A Biocardia director paid $360K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month. Shares held went up 83% with this purchase.
Insider buying
3 insiders in a week, 8th time since 2007Traded Sep 19, 2025 · filed 4 days later
A Biocardia director paid $498K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month. Shares held went up 207% with this purchase.
Insider buying
Traded Aug 22, 2025 · filed 3 days later
The CEO of Biocardia paid $1.3K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month.
Peter Altman, President and CEO's past purchases, 90 days after disclosure: 38 buys, median −9.0 pts vs S&P 500, beat it 13 of 38 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.